BioSyent (CVE:RX) Reaches New 12-Month High – Still a Buy?

BioSyent Inc. (CVE:RX)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as C$16.25 and last traded at C$16.16, with a volume of 1571 shares. The stock had previously closed at C$15.99.

BioSyent Stock Performance

The company has a market cap of C$179.46 million, a PE ratio of 18.58 and a beta of 1.00. The company has a quick ratio of 6.91, a current ratio of 2.07 and a debt-to-equity ratio of 6.85. The company has a 50-day moving average of C$14.81 and a 200-day moving average of C$14.74.

Insider Buying and Selling

In other BioSyent news, Director Seyed Ahmad Ashrafi sold 1,884 shares of BioSyent stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of C$14.65, for a total transaction of C$27,600.60. Following the transaction, the director directly owned 37,261 shares of the company’s stock, valued at C$545,873.65. The trade was a 4.81% decrease in their position. Over the last ninety days, insiders sold 5,509 shares of company stock valued at $82,004. Corporate insiders own 33.65% of the company’s stock.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.